The presented literature review examines the structure of the endogenous pulmonary surfactant, as well as the use of exogenous surfactant (Curosurf®) in various pathological conditions of the respiratory system.
The endogenous lung surfactant is a lipoprotein complex that is synthesized by type II alveolar cells. It supports the breathing process and is a major component of the lung's immune defenses.
In clinical practice, about 80% of premature infants develop respiratory distress syndrome (RDS). This condition requires intrabronchial administration of poractant alfa (Curosurf®), which results in reduced respiratory stress and increased survival.
Apart from RDS, lung surfactants are also used in the treatment of asthma. Various mechanisms have been identified by which the surfactant is important for the pathophysiological course of the disease. Synthetic and natural surfactants that suppress the immune response can be used to treat asthma. For example, Alveofact®, Survanta® and Exosurf® lead to concentration-dependent suppression of lymphocyte function and proliferation, and Curosurf® also inhibits neutrophil activation. It also reduces the production of superoxide anions and the release of proinflammatory mediators from monocytes.
Curosurf® is also relevant for Covid 19 associated pneumonia. It is believed that its intrabronchial administration will lead to improved blood oxygenation levels. Also, administration of surfactant would reduce pulmonary edema and improve the excessive inflammatory response found in autopsies of patients with COVID-19.
Ainsworth SB. 2005. Pathophysiology of Neonatal Respiratory Distress Syndrome: Implications for Early Treatment Strategies. Treatments in Respiratory Medicine. 4(6):423–37
Alcorn JL. 2017. Pulmonary Surfactant Trafficking and Homeostasis. In Lung Epithelial Biology in the Pathogenesis of Pulmonary Disease, pp. 59–75. Elsevier
Baur FM, Brenner B, Goetze-Speer B, Neu S, Speer CP. 1998. Natural porcine surfactant (Curosurf) down-regulates mRNA of tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha type II receptor in lipopolysaccharide-stimulated monocytes. Pediatr Res. 44(1):32–36
Becher G. 1985. Lung surfactant prevents allergic bronchial constriction in ovalbumin sensitized guinea pigs. Biomed Biochim Acta. 44(9):K57-61
Djukanović R, Roche WR, Wilson JW, Beasley CR, Twentyman OP, et al. 1990. Mucosal inflammation in asthma. Am Rev Respir Dis. 142(2):434–57
Erpenbeck VJ, Hagenberg A, Dulkys Y, Elsner J, Bälder R, et al. 2004. Natural Porcine Surfactant Augments Airway Inflammation after Allergen Challenge in Patients with Asthma. Am J Respir Crit Care Med. 169(5):578–86
Gallacher DJ, Hart K, Kotecha S. 2016. Common respiratory conditions of the newborn. Breathe (Sheff). 12(1):30–42
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, et al. 2020. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 181(2):271-280.e8
Hohlfeld J, Fabel H, Hamm H. 1997. The role of pulmonary surfactant in obstructive airways disease. Eur Respir J. 10(2):482–91
Hohlfeld JM, Ahlf K, Enhorning G, Balke K, Erpenbeck VJ, et al. 1999. Dysfunction of pulmonary surfactant in asthmatics after segmental allergen challenge. Am J Respir Crit Care Med. 159(6):1803–9
Jarjour NN, Enhorning G. 1999. Antigen-induced airway inflammation in atopic subjects generates dysfunction of pulmonary surfactant. Am J Respir Crit Care Med. 160(1):336–41
Kingma PS, Whitsett JA. 2006. In defense of the lung: surfactant protein A and surfactant protein D. Curr Opin Pharmacol. 6(3):277–83
Kremlev SG, Umstead TM, Phelps DS. 1994. Effects of surfactant protein A and surfactant lipids on lymphocyte proliferation in vitro. Am J Physiol. 267(4 Pt 1):L357-364
Kurashima K, Ogawa H, Ohka T, Fujimura M, Matsuda T, Kobayashi T. 1991. A pilot study of surfactant inhalation in the treatment of asthmatic attack. Arerugi. 40(2):160–63
Liu M, Wang L, Holm BA, Enhorning G. 1997. Dysfunction of guinea-pig pulmonary surfactant and type II pneumocytes after repetitive challenge with aerosolized ovalbumin. Clin Exp Allergy. 27(7):802–7
Liu M, Wang L, Li E, Enhorning G. 1996. Pulmonary surfactant given prophylactically alleviates an asthma attack in guinea-pigs. Clinical & Experimental Allergy. 26(3):270–75
Madan T, Kishore U, Singh M, Strong P, Clark H, et al. 2001. Surfactant proteins A and D protect mice against pulmonary hypersensitivity induced by Aspergillus fumigatus antigens and allergens. J Clin Invest. 107(4):467–75
Mason RJ. 2006. Biology of alveolar type II cells. Respirology. 11(s1):S12–15
Mirastschijski U, Dembinski R, Maedler K. 2020. Lung Surfactant for Pulmonary Barrier Restoration in Patients With COVID-19 Pneumonia. Front. Med. 7:254
Oetomo SB, Dorrepaal C, Bos H, Gerritsen J, van der Mark TW, et al. 1996. Surfactant nebulization does not alter airflow obstruction and bronchial responsiveness to histamine in asthmatic children. Am J Respir Crit Care Med. 153(3):1148–52
Pastva AM, Wright JR, Williams KL. 2007. Immunomodulatory Roles of Surfactant Proteins A and D: Implications in Lung Disease. Proceedings of the American Thoracic Society. 4(3):252–57
Polin RA, Carlo WA, Committee on Fetus and Newborn, American Academy of Pediatrics. 2014. Surfactant replacement therapy for preterm and term neonates with respiratory distress. Pediatrics. 133(1):156–63
Sánchez Luna M, Bacher P, Unnebrink K, Martinez-Tristani M, Ramos Navarro C. 2020. Beractant and poractant alfa in premature neonates with respiratory distress syndrome: a systematic review of real-world evidence studies and randomized controlled trials. J Perinatol. 40(8):1121–34
Speer CP, Halliday HL. 1994. Surfactant therapy in the newborn. Current Paediatrics. 4(1):5–9
Strong P, Reid KBM, Clark H. 2002. Intranasal delivery of a truncated recombinant human SP-D is effective at down-regulating allergic hypersensitivity in mice sensitized to allergens of Aspergillus fumigatus. Clin Exp Immunol. 130(1):19–24
Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, et al. 2019. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update. Neonatology. 115(4):432–50
Taylor G, Jackson W, Hornik CP, Koss A, Mantena S, et al. 2019. Surfactant Administration in Preterm Infants: Drug Development Opportunities. J Pediatr. 208:163–68
Tegtmeyer FK, Gortner L, Ludwig A, Brandt E. 1996. In vitro modulation of induced neutrophil activation by different surfactant preparations. Eur Respir J. 9(4):752–57
Todorova A, Tsvetkova A, Mihaylova S. 2015. The use of controller medications in the management of pediatric bronchial asthma - Dynamic patterns of LTRA (montelukast) use. . 2(3):7
Tsvetkova А, Mihaylova S. INTEGRATING LEGISLATIVE AND HEALTH POLICIES TO PROMOTE CHILD HEALTH. , p. 5
Walti H, Polla BS, Bachelet M. 1997. Modified Natural Porcine Surfactant Inhibits Superoxide Anions and Proinflammatory Mediators Released by Resting and Stimulated Human Monocytes. Pediatr Res. 41(1):114–19
Willems CH, Urlichs F, Seidenspinner S, Kunzmann S, Speer CP, Kramer BW. 2012. Poractant alfa (Curosurf.) increases phagocytosis of apoptotic neutrophils by alveolar macrophages in vivo. Respiratory Research. 13(1):17
Woerndle S, Bartmann P. 1994. The effect of three surfactant preparations on in vitro lymphocyte functions. J Perinat Med. 22(2):119–28
Wright SM, Hockey PM, Enhorning G, Strong P, Reid KB, et al. 2000. Altered airway surfactant phospholipid composition and reduced lung function in asthma. J Appl Physiol (1985). 89(4):1283–92
Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, et al. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579(7798):270–73
